MET, a receptor tyrosine kinase (RTK) implicated in cancers like lung and gastric, drives cellular growth via ATP-dependent signaling, but mutations often confer resistance to inhibitors, requiring evaluation of multiple treatments (Estevam et al. 2024). Here, NTRK1 is linked to cancer.